MedPath

Breast cancer risk assessment model for Indian women

Not yet recruiting
Conditions
Breast cancer
Registration Number
CTRI/2018/06/014362
Lead Sponsor
AIIMS Delhi
Brief Summary

Breast cancer is the most frequent cancer seen in woman. It was initially thought to be a disease of the elderly woman having certain risk factors like early menarche, late menopause, nulliparity, lack of breast feeding and westernised life style (which would also partly explain increased ocurence of the above mentioned risk factors). The incidence of this disease in India is  increasing and it seen to occur in woman at an age which is almost a decade younger than the western counterparts. Also, most of the woman do not harbor the known risk factors as Indian society has largely well preserved family structure where marrige, child birth and breast feeding still are a standard cultural norm. Despite these facts, breast cancer has become the most common cancer in woman in five of the six population based cancer registeries (PBCRs) in India. While Urbanization and adoption of westernized lifestyle may explain the rising incidence in the urban PBCRs in India, the statisticallysignificant increase in age adjusted rate over time (1982–2014) of 1.87% seen even at the rural PBCRs at Barshi makes it all the more important to identify the*“at risk factors*†existing in this ethnic and geographic region of the globe. Because of lack of these classical risk factors in indian woman, the breast cancer risk assessment tools (BRCAT) developed and validated in the western world do not largely apply to our woman and hence underestimate the risk of developing breast cancer in the India woman. Keeping these points in mind, we want to study the risk factors for development of breast cancer present in our Indian woman and try to develop and validate a breast cancer risk assessment tool, which will estimate the risk of developing breast cancer in indian woman. This may also help in developing breast cancer prevention programes and mechanisms in the future. Also, this will help in identifying the “at risk†woman so that they may be selectively  offered image based (mammographic) screening in a resource limited country like ours.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
331
Inclusion Criteria

Women with biopsy-proven breast cancer, as cases; Women >18 years of age not having personnal history of cancer, as controls; Women willing to participate in the study.

Exclusion Criteria

Women who are not willing to participate in the study; Women having known malignancies other than breast carcinoma; For control group: woman with personnal history of cancer.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. To develop an breast cancer risk assessment model applicable to Indian women, as feasible.Duration of study: from start of study till data collection and analysis , approximately 3 years. however no follow up shall be done as part of this study
2.To validate the above breast cancer risk assessment model prospectively.Duration of study: from start of study till data collection and analysis , approximately 3 years. however no follow up shall be done as part of this study
Secondary Outcome Measures
NameTimeMethod
To study the clinico-epidemiologic and reproductive risk factors for breast cancer in Indian woman.
To evaluate the clinical applicability of Gail model 2 (GM2) as a means of estimating 5 year and lifetime risk of breast cancer in Indian woman.Duration of study: from start of study till data collection and analysis , approximately 3 years. however no follow up shall be done as part of this study

Trial Locations

Locations (1)

All India Institute of Medical Sciences, New Delhi

🇮🇳

South, DELHI, India

All India Institute of Medical Sciences, New Delhi
🇮🇳South, DELHI, India
Suhani
Principal investigator
9810534358
drsuhani@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.